Is it time for a moratorium on the use of benzalkonium chloride in eyedrops?

D'andrea, Luca; Montemagni, Marina; Celenza, Giuseppe; Iorio, Roberto; Costagliola, Ciro

D'andrea, Luca; Montemagni, Marina; Celenza, Giuseppe; Iorio, Roberto; Costagliola, Ciro.

Afiliación

D'andrea L; Department of Public Health, University of Naples Federico II, Naples, Italy.
Montemagni M; Department of Neurosciences, Reproductive and Dentistry Sciences, University of Naples Federico II, Naples, Italy.
Celenza G; Department of Biotechnological and Applied Clinical Sciences, University of Aquila, Aquila, Italy.
Iorio R; Department of Biotechnological and Applied Clinical Sciences, University of Aquila, Aquila, Italy.
Costagliola C; Department of Neurosciences, Reproductive and Dentistry Sciences, University of Naples Federico II, Naples, Italy.

Br J Clin Pharmacol ; 88(9): 3947-3949, 2022 09.

Article en En | MEDLINE | ID: mdl-35527385

Asunto(s)

Compuestos de Benzalconio; Glaucoma; Antihipertensivos/uso terapéutico; Compuestos de Benzalconio/efectos adversos; Glaucoma/tratamiento farmacológico; Humanos; Soluciones Oftálmicas

Palabras clave

BAC; OSD; benzalkonium chloride; glaucoma; neuroinflammation; toxicity

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Benzalconio / Glaucoma Límite: Humans Idioma: En Revista: Br J Clin Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google